Relmada Therapeutics, Inc. (RLMD) conducted its fourth quarter and full-year 2025 earnings conference call on March 19, 2026, at 4:30 PM EDT. The company released a press release detailing its business update and financial results for the periods ended December 31, 2025. Management highlighted forward-looking statements with associated risks.
Relmada Therapeutics, Inc. (RLMD), a biopharmaceutical company, hosted its Q4 2025 earnings call on March 19, 2026. Company participants included Sergio Traversa, CEO and Director; Raj Pruthi, Chief Medical Officer of Urology; and Maged Shenouda, Chief Financial Officer. Analysts from firms such as Lifesci Advisors, Mizuho Securities, Jefferies, Lucid Capital Markets, and Piper Sandler joined the call, including Brian Ritchie, Uy Ear, Farzin Haque, Christopher Liu, and Kelsey Goodwin. The call began with the operator noting it was being recorded and available for replay on the company's website. Brian Ritchie from Lifesci Advisors introduced the session, referencing the press release issued that afternoon. He emphasized safe harbor provisions under the Private Securities Litigation Reform Act and cautioned that forward-looking statements could differ materially from expectations due to risks outlined in the press release and SEC filings. Relmada filed its annual report on Form 10-K for the year ended December 31, 2025, after market close on the call date. The discussion included time-sensitive information accurate only as of the broadcast date.